T. Rowe Price Biotech ETF
TDNA
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 1307 Point Street Baltimore MD United States of America 21231
- IPO Date
- Sep 17, 2026
- CIK
- 0001795351
- Website
- troweprice.com
- Similar Companies
- Business
- T. Rowe Price Biotech ETF (TDNA) is a fully transparent, actively managed exchange-traded fund sponsored by T. Rowe Price Group, Inc., a Baltimore-based investment management firm founded in 1937 and headquartered in Baltimore, Maryland. The fund seeks long-term capital appreciation by investing primarily in biotechnology companies and related emerging technologies that the manager believes may improve the treatment and cure of disease and enhance quality of life; it normally invests at least 80% of net assets in biotechnology securities and is designed to concentrate more than 25% of assets in the biotechnology sector. TDNA is listed on Nasdaq, is expected to hold approximately 60 to 120 companies, and carries an expense ratio of 0.55%. T. Rowe Price offers the ETF within its active ETF lineup alongside other equity, fixed income, multi-asset, digital assets, and thematic strategies, serving financial intermediaries, advisors, and other institutional and retail investors seeking active public-market exposure. In September 2026, T. Rowe Price launched TDNA together with two other active equity ETFs, marking a recent strategic expansion of its ETF platform and adding a new biotechnology-focused vehicle to its product suite. The fund is managed by John Hall, who has 11 years of investment experience at T. Rowe Price.